Read the 2014 Newsletters and recent scientific references 2014, issue 1: FDA Gives Green Light to Human Clinical Trials for Cancer Pain / by DA Lappi / featuring SP-SAP Targeting Talk: Time Course Targeting Tools: Investigating the Itch Pathway 2014, issue 2: Celebrating Twenty Years of Science Advanced Targeting Systems (founded 22 Apr 1994) / featuring 192-IgG-SAP, SP-SAP, Bombesin-SAP …
Targeted conjugates are widely used to escort payloads to specific cell populations in vitro and in vivo for both basic research and pharmaceutical development. Desirable traits of a Targeting Agent include high specificity and rapid internalization. The Targeting Agent can be an antibody, peptide, protein, or any other molecule that recognizes a cell- surface marker. …
Targeting Tools: ZAP Biotin-Z Internalization Kit Read More »
ATS is pleased to announce Beta-release of a wide array of targeted toxins for use in eliminating specific cell types. This Beta-Testing Program will make new conjugates available to our customers sooner. Each of the Beta products will have: Saporin activity confirmed, Peptide sequences published/confirmed, and/or Antibody binding specificity published/confirmed. Beta Products have not been …
Dog with bone cancer jumps for joy over new treatment that made him pain-free after one dose! Otis, the golden retriever, was in his golden years when bone cancer pain threatened to shorten his life. As a participant in a clinical trial aimed at pet dogs, he was given a single treatment with a pain …
Based on the recent publication by: Brown DC, Agnello K. (2013) Intrathecal substance p-saporin in the dog: efficacy in bone cancer pain. Anesthesiology 119(5):1178-1185 and the October 2013 press release by the American Society of Anesthesiologists, “Man’s best friends’ chronic pain relieved with new treatment, study finds: Findings could be useful to human cancer patients.” …